myocardial infarction
Conditions
Brief summary
The primary bleeding endpoint is time to first Bleeding Academic Research Consortium type 2, 3, or 5 bleeding, The primary patient-oriented ischemic clinical endpoint is time to first composite of all-cause mortality, Myocardial Infarction, stroke, or any coronary revascularization
Detailed description
BARC type 3 or 5 bleeding, BARC type 5 bleeding, TIMI minor or major bleeding and its individual components, All-cause mortality, Myocardial infarction, Stroke, Any coronary revascularization, Cardiovascular mortality, The composite of all-cause mortality, MI, or stroke, Net adverse clinical events (NACE), a composite of all-cause mortality, MI, stroke, any coronary revascularization, or type 2, 3, or 5 BARC bleeding
Interventions
Sponsors
Montreal Heart Institute
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary bleeding endpoint is time to first Bleeding Academic Research Consortium type 2, 3, or 5 bleeding, The primary patient-oriented ischemic clinical endpoint is time to first composite of all-cause mortality, Myocardial Infarction, stroke, or any coronary revascularization | — |
Secondary
| Measure | Time frame |
|---|---|
| BARC type 3 or 5 bleeding, BARC type 5 bleeding, TIMI minor or major bleeding and its individual components, All-cause mortality, Myocardial infarction, Stroke, Any coronary revascularization, Cardiovascular mortality, The composite of all-cause mortality, MI, or stroke, Net adverse clinical events (NACE), a composite of all-cause mortality, MI, stroke, any coronary revascularization, or type 2, 3, or 5 BARC bleeding | — |
Outcome results
None listed